Highlights Novartis AG

Stocks

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:32 2026-07-10 EDT			5-day change	1st Jan Change
124.28 ^CHF	-0.02%		-2.85%	+13.39%

07-08	Lancelot Sweden fell 0.8% in June, BioArctic slid despite Eli Lilly deal	FW
07-07	US FDA approves Vera's kidney disease drug	RE

Highlights

07-06	Novartis to Buy UK's Myricx Bio in $1.5 Billion Deal	MT
07-06	Novartis AG entered into an agreement to acquire Myricx Pharma Ltd from Sofinnova Partners SAS and others for $1.5 billion.	CI
07-06	Novartis to Buy Myricx Bio for Up to $1.5 Billion -- Update	DJ
07-06	Novartis to Buy Myricx Bio in Up to $1.5 Billion Deal	MT
07-06	Correction to Novartis Article	DJ
07-06	Novartis to acquire Myricx Bio
07-06	Novartis to Buy Myricx Bio for Up to $1.5 Billion	DJ
07-06	Novartis to acquire UK-based Myricx Bio for up to $1.5 billion	RE
07-06	Novartis to Buy UK's Biotech Myricx Bio for $1.5 Billion	MT
07-06	Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients	DJ
07-02	Novartis AG Receives European Commission Approval For Itvisma For Spinal Muscular Atrophy	CI
07-02	BofA Expects 'Small' Novartis Q2 Consensus Miss, Unchanged FY26 Outlook; Buy Rating Kept	MT
07-02	Novartis Spinal Muscular Atrophy Treatment Receives European Commission Approval	MT
06-26	Novartis Europharm Wins European Medicines Agency's Positive Opinion for Hypercholesterolemia Drug	MT
06-24	Antares Therapeutics, Inc. and Novartis Enter Agreement to Discover, Develop and Commercialize First-In-Class Cancer Therapies	CI
06-24	Becoming Rentable and Novartis Join Smashing My Limits and Going Places Campaign to Expand Accessible Lodging for People Living with Sma	CI
06-12	Novartis AG Presents RemIND Data At EAACI Demonstrating Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria	CI
06-11	Novartis says rare muscle disease drug shows promise in early trial	RE
06-11	Novartis AG Announces Phase I/II Study Results For Delpacibart Braxlosiran In Facioscapulohumeral Muscular Dystrophy	CI
06-11	Novartis Says Early-to-Mid Stage Study for Muscular Dystrophy Drug Meets Main Goal	MT
06-04	Novartis Reports Final 2.5-Year Phase III ALIGN Results Showing Slower Kidney Function Decline With Vanrafia Versus Placebo In Adults With IgA Nephropathy	CI
06-03	Novartis Presents New Cosentyx Data In Polymyalgia Rheumatica Demonstrating Statistically Significant Clinically Meaningful Difference In Sustained Remission Rates Versus Placebo And Significant Steroid Sparing	CI
06-01	Novartis Reports 144-Week Data from Asc4first Trial of Scemblix Demonstrating Superior Efficacy and Safety in Newly Diagnosed Cml	CI
05-31	Novartis Demonstrates Consistent Efficacy Of Pluvicto In Metastatic Hormone-Sensitive Prostate Cancer And Presents Promising Phase 1 Data For Actinium-Based RLT	CI
05-22	Novartis Wins European Medicines Agency's Positive Opinion on Overgrowth Drug	MT